ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy

Gilead's Kite Pharma is waiting for phase 3 data that show its Yescarta can help previously treated diffuse large B-cell lymphoma (DLBCL) patients earlier in their treatment course. But in the meantime, it’s trumpeting phase 2 data in newly diagnosed lymphoma patients that it thinks bode well for its forthcoming results.